Tesamorelin dosing & administration
The only FDA-approved peptide specifically designed to melt away stubborn belly fat by telling your brain to release more growth hormone naturally—working with your body's own systems rather than replacing them [6].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Timing
Best time to take
Inject in the morning on an empty stomach, at least 30 minutes before eating. This aligns with your natural cortisol awakening response and may optimize growth hormone release patterns.
With food?
Do NOT inject with food. Tesamorelin should be given on an empty stomach for optimal absorption. Wait at least 30 minutes after injection before eating breakfast.
If stacking
If using with other growth hormone secretagogues, separate injections by several hours. Some practitioners alternate between tesamorelin and other GHRH peptides rather than using them the same day. Never combine with exogenous GH—choose one or the other [16].
Adjusting your dose
Increase if
- You've been on the starting dose for 4+ weeks with no issues
- IGF-1 levels haven't increased meaningfully on lower doses
- Your physician recommends the standard FDA-approved dose
Decrease if
- You experience significant joint pain or swelling
- Blood glucose levels rise substantially
- Fluid retention becomes uncomfortable
- Injection site reactions are severe or persistent
Signs of right dose
- Measurable reduction in waist circumference over 3-6 months
- Improved triglyceride levels on blood work [1]
- IGF-1 levels in the upper normal range
- Better body image and reduced belly appearance distress [1]
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin into fatty tissue)—this is the only approved administration route
Best sites
Storage
Before reconstitution
Store powder in refrigerator at 36-46°F (2-8°C). Keep in original carton to protect from light. Do not freeze. Check expiration date on package—stable until that date if properly stored.
After reconstitution
Refrigerate reconstituted solution at 36-46°F (2-8°C). Use within 14 days for Egrifta SV (original Egrifta had shorter stability). Never freeze reconstituted solution. If solution becomes cloudy or contains particles, do not use.
Signs of degradation — discard the vial
Sample daily schedule
Morning (before breakfast)
1.4-2 mg depending on formulation injection
Site: Rotate between left and right abdomen
Inject on an empty stomach at least 30 minutes before eating. Consistency is key—try to inject at the same time each day. Morning dosing may align better with natural GH release patterns.
Safety
Is it safe?
Side effects
Commonly reported: Injection site reactions, Joint pain (arthralgia), Muscle pain (myalgia), Peripheral edema
Less common: Carpal tunnel symptoms, Elevated blood glucose
Stop and seek help if
- Severe allergic reaction occurs—stop immediately and seek emergency care
- Visceral fat has not decreased after 3 months of treatment (per FDA guidance) [6]
- Blood glucose becomes uncontrolled despite adjustments
- Development of new or worsening malignancy [6]
- Pregnancy occurs or is planned [6]
- Intolerable side effects that don't resolve with dose adjustment
Tesamorelin is an FDA-approved prescription medication that should only be used under physician supervision. Never start, stop, or adjust your dose without consulting your prescribing healthcare provider. This information is educational and does not constitute medical advice.
Flagged pairings
- Insulin — Tesamorelin can increase blood glucose, potentially requiring insulin dose adjustments. Monitor closely.
- Oral diabetes medications — May need dose adjustment as tesamorelin affects glucose metabolism. Work with your endocrinologist.
- Growth hormone — Do not combine. Using both would be redundant and could cause excessive GH effects.
Published research
What the studies show
Falutz J, Mamputu JC, Potvin D, et al. · 2010
In this combined analysis of over 800 HIV patients, tesamorelin reduced visceral fat by an average of 15.4% compared to placebo at 26 weeks. The reduction was maintained at 52 weeks in those who continued treatment. It also improved triglycerides by 12% and significantly improved how patients felt about their belly appearance.
Stanley TL, Falutz J, Marsolais C, et al. · 2012
Patients who achieved at least 8% reduction in visceral fat (called 'responders') experienced significantly greater improvements in triglycerides, glucose control, and adiponectin levels compared to non-responders. This shows that the metabolic benefits directly correlate with how much visceral fat you lose.
Baker LD, Barsness SM, Borson S, et al. · 2012
In a 20-week trial with 152 adults (some with mild cognitive impairment), tesamorelin improved executive function and showed a trend toward better verbal memory. IGF-1 levels increased 117% and body fat decreased 7.4%. This suggests tesamorelin may have brain health benefits beyond just fat reduction.
Stanley TL, Fourman LT, Feldpausch MN, et al. · 2019
In people with HIV and fatty liver disease, tesamorelin reduced liver fat by 37% relative to placebo over 12 months. Remarkably, 35% of tesamorelin patients achieved liver fat levels below 5% (essentially normal) compared to only 4% on placebo. This opens up potential new uses for liver health.
Dhillon S · 2011
This comprehensive review confirmed tesamorelin's effectiveness and safety profile. It noted that while visceral fat reduces significantly, subcutaneous fat stays stable—an important distinction because subcutaneous fat is metabolically healthier. Side effects were manageable and serious events occurred in less than 4% of patients.
Theratechnologies Inc. / U.S. FDA · 2019
Falutz J, Potvin D, Mamputu JC, et al. · 2010
In this 12-month trial of 404 HIV-infected patients, visceral fat fell 10.9% on tesamorelin versus 0.6% on placebo over the first 6 months, and was about 18% below baseline in patients who continued the drug for 12 months. Patients re-randomized from tesamorelin to placebo rapidly lost the visceral fat reduction they had gained. No change in glucose parameters was observed.
Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P · 2007
Adding a trans-3-hexenoyl group to the first amino acid of GHRH(1-44) made the peptide resistant to dipeptidyl aminopeptidase-IV breakdown, slowing its degradation in rat, dog and human plasma and prolonging how long it stayed in circulation. The modified peptide still raised growth hormone and IGF-1 in pigs, rats and dogs. Apparent elimination half-life in dogs was 21 to 45 minutes.
Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV · 2025
This review describes GHRH binding to the pituitary GHRH receptor, a G protein-coupled receptor expressed mainly on somatotroph cells of the pituitary. Receptor activation raises intracellular cAMP, and the resulting signaling phosphorylates CREB, which with its coactivators p300 and CREB-binding protein increases growth hormone gene transcription.
Stanley TL, Grinspoon SK · 2015
This review of human studies reports that GHRH treatment increases the body's own basal and pulsatile growth hormone secretion without changing pulse frequency, and that giving GHRH preserves the normal IGF-1 negative feedback on pituitary GH release, with IGF-1 monitored to keep levels in the physiological range. It also notes that increased visceral fat and reduced GH each contribute independently to dyslipidemia, systemic inflammation, and cardiovascular risk, and that GHRH treatment reduces visceral fat and improves these markers.
Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK · 2012
In obese adults without HIV who had reduced growth hormone secretion, tesamorelin reduced visceral fat (treatment effect -35 cm2) while body weight did not differ significantly from placebo (0.1 kg vs 0.9 kg, P = 0.52). The authors note that weight stayed flat because fat mass fell and lean mass rose by similar amounts.
Neeland IJ, Ross R, Despres JP, et al. · 2019
This joint position statement summarises three decades of epidemiological evidence that visceral adipose tissue, measured by CT or MRI, is an independent risk marker for cardiovascular and metabolic illness and death, and reviews visceral and ectopic fat as risk factors for type 2 diabetes, atherosclerosis, and cardiovascular disease.
Colon G, Saccon T, Schneider A, et al. · 2019
This review of growth hormone and aging states that GH levels fall gradually after puberty, and that after the third decade of life the decrease is about 14% per decade.
Reed ML, Merriam GR, Kargi AY · 2013
This review reports that the most common side effects of growth hormone treatment in adults come from fluid retention, and lists peripheral edema, arthralgia, carpal tunnel syndrome, paresthesias, and worsening glucose tolerance among them. It also notes that these effects became less frequent once dosing moved from high weight-based regimens to low starting doses titrated upward, and that the side effect profile of replacement doses does not apply to supraphysiologic dosing.
Erman A, Veilleux A, Tchernof A, Goodyer CG · 2011
Growth hormone receptor mRNA was measured in omental (visceral) and subcutaneous fat from 55 women across the range of body weight. Receptor expression was 2 to 3 fold lower in obese than lean women in both depots, and in lean women receptor levels were higher in omental than in subcutaneous fat, a depot difference that disappeared with obesity.
Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T · 2000
Healthy men were given injections of the 20K isoform of human growth hormone. Their own 22K growth hormone secretion was markedly suppressed in a time-dependent manner, showing that injected growth hormone shuts down the pituitary's own GH release.
Head to head
Tesamorelin compared
Studied for
Conditions Tesamorelin has been researched in
Want the full picture?
The complete Tesamorelin research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.